COMMUNIQUÉS West-GlobeNewswire

Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
24/02/2026
Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3 GLEN ALLEN, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical- [...]
Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples
24/02/2026
Mainz Biomed to Present Industry Leading Results: 100% Sensitivity and 95% Specificity BERKELEY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company [...]
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
24/02/2026
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the [...]
Indivior to Participate in Upcoming Investor Conferences
24/02/2026
RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: Barclays 28th Annual Global [...]
Apogee Therapeutics to Participate in Upcoming March Conferences
24/02/2026
SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th Annual Health [...]
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
24/02/2026
Nomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA’s review of available clinical data from open label study FDA written communications after [...]
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
24/02/2026
NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity
24/02/2026
Data presented at 16 th World ADC London Summit with lead programme in colorectal cancer highlight the promise of Promatix’s proteomics-based platform to optimise cis-bispecific antibody-drug conjugate (ADC) discovery [...]
Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
24/02/2026
Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarter Full year 2025 revenue of $738 million, a year-over-year increase of 16 [...]
Avalo Therapeutics to Participate in Upcoming Investor Conferences
24/02/2026
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory [...]
Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract
24/02/2026
First of two Pivotal Efficacy Studies support future sNDA submission for Treatment of Pulmonary Anthrax Oral NUZYRA Tablets Produced in the U.S. as a Result of the Company's Onshoring Initiative were Procured by BARDA [...]
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
24/02/2026
Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep clinical development and product approval experience to support [...]
Porosome Therapeutics Announces New Porosome-Targeted Medicines Developed Using AI
24/02/2026
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced the development of novel first-in-class porosome-targeting small molecules and blood brain barrier (BBB) [...]
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
24/02/2026
In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release constitutes a “ [...]
Glass House Brands Board of Directors Establishes Product Expansion Committee to Support New Product and Business Development
24/02/2026
LONG BEACH, Calif. and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest- [...]
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution
24/02/2026
– ARCALYST ® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively – – ARCALYST 2026 net product revenue expected to be $900 - $920 million – – KPL-387 Phase 2 [...]
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
24/02/2026
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitor NLRP3 inhibitors are a major new class of compounds linked to a broad [...]
Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders
24/02/2026
Aptose Biosciences and Hanmi Pharmaceutical to Further Extend Loan Agreement to Continue Development of Tuspetinib in Frontline Triplet Therapy for AML SAN DIEGO and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aptose [...]
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases
24/02/2026
Jeito Capital, Novo Holdings and other healthcare investors join Series A syndicate led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds Additional capital further supports clinical development of ALV [...]

Pages